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The increase of infections worldwide caused by multidrug-resistant
organisms has resulted in a growing challenge to provision of adequate pa-
tient care, especially to patients who are critically ill. Professional societies,
including the Infectious Diseases Society of America, have sought legislation
to increase antimicrobial research and development to combat these multi-
drug-resistant pathogens [1]. One of the identified pathogens of primary
concern is the gram-negative bacteria of the genus Acinetobacter. Although
historically considered organisms of low virulence (and pathogenicity),
Acinetobacter are increasingly recognized as the cause of infections, espe-
cially in intensive care units.
Crit Care Clin 24 (2008) 237–248The bacteria
The taxonomy of Acinetobacter has not been defined adequately. Cur-
rently, the genus includes named (Box 1), proposed, and genomic species
(or genospecies) (www.bacterio.cict.fr/a/acintobacter.html). Most disease
is caused by a complex of four phenotypically similar genospecies (1, 2, 3,
and 13TU). Two of them are named A calcoaceticus (genospecies 1) and
A baumannii (genospecies 2), and the group are commonly referred to as
the A calcoaceticus-A baumannii complex. Acinetobacter are gram-negative
aerobic coccobacilli with a tendency to retain crystal violet on GramDisclaimer: The opinions or assertions contained herein are the private views of the au-
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Box 1. Named species of Acinetobacter
Acinetobacter (genus) (1954)
A baumannii (1986)
A baylyi (2003)
A bouvetii (2003)
A calcoaceticus (1911)
A gerneri (2003)
A grimontii (2003)
A haemolyticus (1963)
A johnsonii (1986)
A junii (1986)
A lwoffii (1940)
A parvus (2003)
A radioresistens (1988)
A schindleri (2001)
A tandoii (2003)
A tjernbergiae (2003)
A towneri (2003)
A ursingii (2001)
Year in parentheses represents year of description in the
literature.
Data from Euzeby JP. List of prokaryotic names with standing in nomenclature.
Available at: http://www.bacterio.cict.fr/a/acinetobacter.html.
238 MURRAY & HOSPENTHALstaining, thus they are occasionally misidentified as gram-positive bacteria.
They can persist on inanimate surfaces for prolonged periods of time (3 days
to 5 months) and can be detected on various hospital equipment, including
bedrails, curtains, and ventilation equipment (eg, ventilation [ambu] bags
and ventilation filters) [2–4]. Colonization of patients, health care workers,
and healthy individuals occurs, although there is substantial genotypic and
phenotypic variability between isolates recovered from these groups; isolates
from patients with prolonged hospitalizations typically are more resistant
[5–7]. Long-term colonization has been documented [8].Epidemiology
Within the United States, Acinetobacter is a common cause of nosoco-
mial infections. It caused 6.9% of nosocomial pneumonias, 2.4% of blood-
stream, 2.1% of surgical site, and 1.6% of urinary tract infections in 2003
[9]. Outbreaks are recognized as being associated with hospital equipment,
including that used in wound treatment (pulsatile lavage) [10]. An
increasing incidence of Acinetobacter infections is being recognized
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advanced from the fourth most common bacteria resulting in bloodstream
infections in 1997 to the most frequent cause in 2002 [11]. Since the involve-
ment of the US military in overseas operations in Iraq and Afghanistan, nu-
merous casualties have been infected or colonized with Acinetobacter
[12–14]. Disease in this group of patients has included bone and soft tissue
infections after combat trauma, pneumonia, bloodstream, and central ner-
vous system infections. Currently, the most likely source of these infections
seems to be nosocomial transmission throughout the medical evacuation
chain in Iraq, Germany and US hospitals [15]. Isolates recovered from mil-
itary personnel are genetically related or identical to isolates recovered in
England and throughout Europe [16,17]. Apart from the military, there
also have been reports of Acinetobacter in civilian patients medically evacu-
ated across international borders [18]. Interhospital transmission of resistant
Acinetobacter has been associated with transferring patients between hospi-
tals [19]. The role of community-associated infections, especially pneumo-
nia, is under debate because patients reported in these studies are often at
higher risk because of comorbidities [20–23].Virulence
The true disease impact (attributable morbidity and mortality) of Acine-
tobacter has been an ongoing debate for the past 30 years, chiefly because of
the difficultly of differentiating colonization from infection with these organ-
isms. The recent military experience with Acinetobacter has not been able to
find attributable mortality in our young, healthy population, but rather
an association with longer hospital stays and more surgical procedures
[12–14,24]. Numerous studies in nonmilitary patients have reported increased
morbidity, including longer length of hospitalizations, more intensive care
unit days, and an overall increase in hospital costs [25–27]. Some studies
have reported attributable mortality, especially in patients with imipenem-
resistant isolates who were not provided adequate therapy initially [28–30].
Risk factors associated with poor outcomes with Acinetobacter infections
include elevated APACHE II scores, underlying chronic disease, mechanical
ventilation, multiple trauma, neutropenia, previous antimicrobial exposure,
blood transfusion, and colonization density [31–35]. Interestingly, appropri-
ate or inappropriate antimicrobial therapy has not always been predictive of
mortality [13,30,36].Antimicrobial resistance
One of the hallmarks of Acinetobacter is its ability to develop resistance
to a wide range of antimicrobial agents. Resistance has been associated with
an 86-kb chromosomal region, or resistance island, that is responsible for
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[24,37,38]. Surveillance studies have revealed an increase of multidrug-
resistant isolates being recovered from Europe, the Asian-Pacific region,
Latin America, and North America over the last 3 to 5 years [38–40]. Aci-
netobacter isolates have been noted to develop resistance while on therapy
even to recently approved antimicrobial agents, such as tigecycline
[38,41,42]. Different resistance patterns have been reported even within hos-
pital outbreaks with proven clonal isolates of Acinetobacter, which makes
the antibiotic profile (antibiogram) an inaccurate method for assessing clon-
ality [43–45]. This inaccuracy makes evaluation or even recognition of
Acinetobacter outbreaks in a hospital environment that much more difficult.
Emergence of resistance within any health care facility is likely caused by an-
timicrobial pressure and cross-transmission between patients with resistant
isolates [46–48].
Management of Acinetobacter infections is challenging because of the
broad array of resistance and the pathogen’s ability to rapidly develop
new resistance. Even the testing for antimicrobial resistance in Acinetobacter
continues to present difficulties to the treatment of infections because of these
bacteria. The standard for determining antimicrobial resistance profilesd
broth microdilutiondexhibits subtle differences in growth patterns, particu-
larly for b-lactams, which leads to discrepancies in defining the level of
resistance for ampicillin-sulbactam, piperacillin, cefepime, cefotaxime, cef-
triaxone, tetracycline, and doxycycline [38,49]. The agent with the most con-
sistent in vitro activity, colistin, is faced with its own testing challenges.
Results produced by E-test do not always correlate with those obtained
by microdilution testing [50].
Recently, in vitro testing of Acinetobacter revealed subpopulations that
are resistant (heteroresistance) to colistin, which results in growth of the
bacteria in the face of high levels of colistin. The recovered heteroresistant
organisms may be less fit, have increased susceptibilities to other antimicro-
bial agents, and have decreased ability to form biofilms [38,51–53]. Colistin
susceptibility testing in the clinical microbiology laboratory is commonly
performed by disk diffusion with colistin sulfate–impregnated disks. In clin-
ical practice, colistimethate sodium is used because it is less toxic than colis-
tin sulfate and is available in intravenous formulations. Colistimethate
sodium is also less potent than colistin sulfate [54].
In vitro synergy testing has been evaluated with numerous combinations,
including azithromycin, rifampin, doxycycline, and imipenem. These studies
have reported variable synergistic and antagonistic activity and varying re-
sults based on different testing methods used [52,53,55–57]. When synergis-
tic combinations have been tested in animal models, the outcome benefit
between mono- and dual therapy also has been mixed [58–60]. An assess-
ment of an infrequently used testing methoddpeak and trough serum bac-
tericidal activitydfound that peak concentrations of antimicrobial agents
had a moderate correlation but not causal association with outcome [61].
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Antimicrobial agents that are typically active against Acinetobacter infec-
tions are the carbepenems (ie, imipenem/cilastatin and meropenem) (al-
though isolates are typically more susceptible to imipenem), amikacin,
sulbactam, colistin, rifampin, and tetracyclines. In some studies, less than
75% of isolates are susceptible to many or all of these agents [38–40]. The
use of combination therapy is controversial in the treatment of gram-negative
bacterial infections in general, because there is no proven improvement in
mortality or decrease in length of stay, and some studies report increased
toxicity [62,63]. At this time, therapy for Acinetobacter infections should
rely on in vitro testing to select antimicrobial agents (Table 1).
In the face of broad-spectrum antimicrobial resistance, colistin typically
retains activity; however, the clinical impact of colistin heteroresistance re-
ported with some isolates is currently unknown. Colistin was historically
considered too nephrotoxic and neurotoxic for routine clinical use, but re-
cent use revealed that its toxicity profile is not dissimilar to other agents
used in critically ill patients [54,64]. There is concern about the penetrationTable 1
Antimicrobial agents suggested for use in the treatment of Acinetobacter infections
Antimicrobial class Specific agent (route) Comments
Polymyxin Colistimethate sodium (IV) Agents with the overall highest
susceptibility rates
Concern of the recently described
heteroresistance
Carbapenem Imipenem-cilastatin (IV) Imipenem typically is associated with
higher susceptibility rates than
meropenem
Aminoglycoside Amikacin (IV) Amikacin typically is associated with
higher susceptibility rates than
tobramycin, which are higher than
gentamicin
Tetracycline Minocycline (PO) Minocycline typically is associated
with higher susceptibility rates than
doxycycline, which are higher than
tetracycline
There are no CLSI criteria for
tigecycline susceptibility; however,
clinical resistance has been reported
and can develop on therapy
These are bacteriostatic agents with
unproven efficacy in severely ill
patients
Minocycline is available only in oral
formulation in the United States
Abbreviations: CLSI, Clinical and Laboratory Standards Institute (formerly National Com-
mittee on Clinical Laboratory Standards [NCCLS]); IV, intravenous; PO, oral.
242 MURRAY & HOSPENTHALof this agent into lung tissue when given parenterally, although clinical suc-
cess has been reported. There currently seems to be increased use of colistin
in a nebulized form, although this is not an FDA-approved indication for
this drug [65,66]. Colistin therapy for patients with imipenem-resistant iso-
lates seems to have equal efficacy to therapy with imipenem in patients with
imipenem-susceptible isolates [64].
Dosing of colistin is based on the manufacturer recommendations, with
doses of 2.5 to 5.0 mg/kg/d in two to four doses suggested for Coly-Mycin
M Parenteral (Monarch Pharmaceutical, Inc., Bristol, Tennessee) and 1 to 2
million IU three times a day for Colomycin Injection (Pharmax Limited,
Bexley, Kent, United Kingdom) [54]. In vitro data looking at postantibiotic
effect and the development of heteroresistant colonies suggest that more fre-
quent dosing may allow improved efficacy and decrease toxicity [67,68]. Tet-
racyclines, including doxycycline, minocycline, and tigecycline, have activity
in vitro and seem to be effective in reports of clinical use. Further evaluation
is needed because these agents are only bacteriostatic and resistance occur-
ring on therapy has been described [69,70]. Positive results with the use of
doxycyline or the combination of polymyxin B and doxycycline have been
reported [69]. Rifampin is another antimicrobial agent that typically retains
in vitro activity against Acinetobacter. As in other indications for use of this
agent, rifampin should not be used as monotherapy in these infections.
There have been reports of rifampin resistance developing when this agent
is used in combination with other antibiotics to which resistance is known
[71].
The most common infections seen with Acinetobacter are nosocomial
pneumonias, bacteremia, surgical site infections, and urinary tract infec-
tions, but occasionally patients develop endocarditis or central nervous sys-
tem infections. For endocarditis, especially prosthetic valve infections, the
overall outcome is favorable after initiating therapy with an active antimi-
crobial agent [72]. Central nervous system infections also typically have
good outcomes. Imipenem and meropenem have adequate central nervous
system penetration. In the case of multidrug-resistant isolates infecting the
central nervous system, combination therapy, including systemic and intra-
ventricular or intrathecal colistin therapy, has been used with overall good
outcomes [73–75]. Some courses of therapy were associated chemical menin-
gitis [73,74].
Alternative techniques to improve efficacy of antimicrobial therapy, espe-
cially with isolates that are resistant to all agents tested in vitro, include pro-
longing infusion times (meropenem and imipenem) and using continuous
infusion (colistin) [76,77]. Sulbactam, although traditionally thought not
to have significant antibacterial activity when used alone, has activity
against Acinetobacter. High doses of ampicillin-sulbactam have been used
clinically and seem to be effective in treating infections without report of in-
creased adverse events [78]. Randomized, controlled studies are needed to
determine the ideal antimicrobial therapy and the best methods to deliver
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[79].Infection control
Given the broad array of resistance associated with Acinetobacter, the
role of preventing spread of this pathogen to other patients is paramount.
The recently released Centers for Disease Control and Prevention (CDC) in-
fection control recommendations indicate that hospitals with increased rates
of multidrug-resistant Acinetobacter should take more aggressive infection
control measures to control and prevent further nosocomial transmission
[80]. Although challenging, implementation of aggressive infection control
measures can control outbreaks of Acinetobacter infections [81–83]. Mea-
sures that are more likely to be effective include increased staff education,
single-use items for individual patients, hand hygiene, cohorting, and isola-
tion. Antibiotic control programs also seem effective in modifying the devel-
opment of resistance to antibiotics under restriction [84]. These control
programs may lead to the development of resistance to other antimicrobials,
however, as was the case in one report in which controlling the use of cipro-
floxacin and ceftazidime resulted in increased Acinetobacter-associated imi-
penem and amikacin resistance [84]. Antibiotic control programs also can
alter (select for other) pathogens responsible for infections within the hospi-
tal. Because antibiograms cannot always predict the clonality of an outbreak
strain, consideration of molecular typing Acinetobacter isolates should be
considered.Summary
Acinetobacter is a formidable challenge to managing critically ill patients.
This pathogen’s ability to rapidly develop antimicrobial resistance to all
currently available antimicrobial agents is concerning because increasing
data support attributable mortality to these bacteria when associated
with hospitalized patients with comorbidities and severe illness. Individual
patient therapy should be directed by in vitro testing. Although imipenem-
cilastatin seems to be a preferred agent for treating these infections, resis-
tance to this antimicrobial also seems to be increasing. The role of dual
therapy is currently unclear and might be associated with increased toxic-
ities without proven synergy or ability to prevent the development of resis-
tance. Colistin seems to be a reliable alternative treatment agent, but
reports of the development of resistance in vitro after drug exposure are
concerning. Infection control and antibiotic control measures might have
the greatest impact on these bacteria. Continued efforts are needed to de-
velop new antimicrobial agents against this pathogen and assess the ideal
currently available agents.
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